ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.341,13
0,74%
S&P 500
5.464,62
-0,16%
US Dollar vs BRL
5,44289
0,21%
Bitcoin
64.275,90
0,29%
Brent Oil
84,39
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Imunon Inc (IMNN)

  7. Imunon Inc (IMNN) Notícias

IMNN

Imunon (IMNN)

Imunon Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMNN
DataHoraFonteTítuloCódigoCompanhia
14/06/202407:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
13/06/202410:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
10/06/202415:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
05/06/202409:30GlobeNewswire Inc.First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical TrialNASDAQ:IMNNImunon Inc
23/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNNImunon Inc
15/05/202417:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMNNImunon Inc
15/05/202409:30GlobeNewswire Inc.Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingNASDAQ:IMNNImunon Inc
13/05/202410:00GlobeNewswire Inc.IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyNASDAQ:IMNNImunon Inc
13/05/202409:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNNImunon Inc
13/05/202409:00GlobeNewswire Inc.IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
08/05/202409:00GlobeNewswire Inc.IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEONASDAQ:IMNNImunon Inc
06/05/202412:00GlobeNewswire Inc.IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024NASDAQ:IMNNImunon Inc
18/04/202409:30GlobeNewswire Inc.IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
11/04/202409:00GlobeNewswire Inc.IMUNON Reports Compliance with Nasdaq Listing RequirementsNASDAQ:IMNNImunon Inc
28/03/202409:00GlobeNewswire Inc.IMUNON Reports 2023 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
25/03/202409:30GlobeNewswire Inc.IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesNASDAQ:IMNNImunon Inc
21/03/202418:00GlobeNewswire Inc.IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024NASDAQ:IMNNImunon Inc
13/03/202409:00GlobeNewswire Inc.IMUNON Files IND Application to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
12/03/202418:00GlobeNewswire Inc.IMUNON Announces Leadership ChangeNASDAQ:IMNNImunon Inc
29/02/202410:30GlobeNewswire Inc.Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5NASDAQ:IMNNImunon Inc
27/02/202410:30GlobeNewswire Inc.Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
22/02/202410:00GlobeNewswire Inc.IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineNASDAQ:IMNNImunon Inc
09/02/202418:09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IMNNImunon Inc
20/12/202319:15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IMNNImunon Inc
11/12/202310:30GlobeNewswire Inc.IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMNNImunon Inc
14/11/202311:00GlobeNewswire Inc.IMUNON’s VP of R&D to Present at the Vaccines Summit-2023NASDAQ:IMNNImunon Inc
14/11/202310:00GlobeNewswire Inc.IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:IMNNImunon Inc
07/11/202310:30GlobeNewswire Inc.IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023NASDAQ:IMNNImunon Inc
23/10/202309:30GlobeNewswire Inc.IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines CongressNASDAQ:IMNNImunon Inc
19/10/202309:30GlobeNewswire Inc.IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United NationsNASDAQ:IMNNImunon Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMNN

Seu Histórico Recente

LSE
ZHEH
Zhejiang Expressway
ASX
NTLND
New Talisman Gold Mines
EU
XS2014371566
Cartesian Residential Mo...
DGFX
BSHINJAUSDT
Shibnobi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados